Cigarettes smoking and the risk of rehospitalization in patients with schizophrenia
DOI:
https://doi.org/10.12923/j.2081-3910/13.4/a.11Keywords:
schizophrenia, smoking, hospitalizationAbstract
Schizophrenia is a chronic mental disease which, in spite of adequate treatment, brings a high risk of relapse with frequent need for hospitalization. Among many factors affecting the frequency of hospitalization in patients diagnosed with schizophrenia, smoking cigarettes is one of them. Numerous research confirmed higher percentage of smoking schizophrenic patients as compared to patients suffering from other mental illnesses or healthy population. The prevalence of nicotine dependence among schizophrenic patients is explained, inter alia, by relationship with disease symptoms and side effects of the treatment and related attempts of self-medication. Lower premorbid functioning, more acute disease process, higher risk of relapse and somatic disease, are observed in smoking patients group diagnosed with schizophrenia. The course of schizophrenic process could be modified by smoking, through 1) neurobiological changes, as increasing of dopamine activity, 2) enzyme induction responsible for the drug metabolism, and related to this process changes of plasma concentration of neuroleptics. Complexity of the relation between smoking, course of schizophrenic process and risk of rehospitalisation, cannot draw definite conclusions and should be inspiration for further research.
References
1. Pużyński S., Rybakowski J., Wciórka J. Psychiatria. Wrocław; Elsevier Urban&Partner; 2011 tom 2, s.205.
2. Gelder MG., Lopez-Ibor JJ., Andreasen NC. New Oxford Textbook of psychiatry. Oxford: Oxford University Press, 2000: 567-621.
3. Suzuki Y., Yasumura S., F ukao S ., et al. Associated factors of rahospitalization among schizophrenic patients. Psychiatry Clin Neurosci; 57: 555-561.
4. Almond S., Knapp M., Francois C., et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184: 346-351. https://doi.org/10.1192/bjp.184.4.346
5. Harris MG., Henry LP., Harrigan SM., et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res 2005; 79: 85-93. https://doi.org/10.1016/j.schres.2005.05.024
6. Diagnostic and Statistical Manual of Mental Disorders - DSM-IV-TR. 4th ed. Washington DC: American Psychiatric Association, 2002. https://doi.org/10.1176/appi.books.9780890423349
7. Talarowska-Bogusz M., Florkowski A., Zboralski K., Cieślak K., Gałecki P.: Przyczyny i skutki wielokrotnych hospitalizacji w szpitalu psychiatrycznym chorujących na schizofrenię; Pol. Merk. Lek. 2008; XXIV, 140: 101-105.
8. Morgan V., Korten A., Jablensky A.: Modifiable risk factors for hospitalization among people with psychosis: evidence from the National Study of Low Prevalence (Psychotic) Disorders. Austral. & N. Zeal. J. Psychiatry. 2006; 40(8): 683-690. https://doi.org/10.1080/j.1440-1614.2006.01868.x
9. Munk-Jorgenses P., Mortensen P.B., Machon R.A.: Hospitalization patterns in schizophrenia a 13 years followup. Schizophrenia Res., 1991, 4:1-9.
10. Johnstone P., Zolese G.: Systematic review of effectiveness of planned short hospital stays for mental health care. Br. Med. J., 1999. 318:1387-1390. https://doi.org/10.1136/bmj.318.7195.1387
11. Schwarz K., Iancu I., Stryjer R., Chelben J., Kotler M., Weizman A., Rehavi M. Reduced platelet vesicular monoamine transporter density in smoking schizophrenia patients. Eur Neuropsychioharmaciogy. 2005; 15: 557-561. https://doi.org/10.1016/j.euroneuro.2005.02.005
12. Ciara K., Robin G. Mccreadie Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999, 156: 1751-1757. https://doi.org/10.1176/ajp.156.11.1751
13. De Leon J., Diaz FJ. A meta-analysis of worldwide studies demonstrates an association betweens schizophrenia and tobacco smoking behaviors. Schizophrenia Res. 2005; 76: 135-157. https://doi.org/10.1016/j.schres.2005.02.010
14. Salokangas RKR., Honkonen T., Stengard E., Koivisto AM., Hietala J. Cigarette smoking in long-term schizophrenia. Eur Psychiatry 2006; 21: 219-223. https://doi.org/10.1016/j.eurpsy.2005.07.008
15. Masterson E., O’shea B.: Smoking and ligancy in schzophrenia. Br J Psychiatry. 1984; 145: 429-432.
16. Hughes JR., Hatsukami DK., Mitchell JE., Dahlgren LA.: Prevalance of smoking among psychotic outpatients. Am J Psychiatry. 1986; 143: 993-997.
17. Goff DC., Henderson DC., Amico E.: |Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992; 149: 1189-1194. https://doi.org/10.1176/ajp.149.9.1189
18. Ziedonis DM., Kosten TR., Glazer WM., Frances RJ.: Nicotine dependence and schizophrenia. Hosp Community Psychiatry 1994; 45: 204-206. https://doi.org/10.1176/ps.45.3.204
19. Diwan A., Catine M., Pomerlau CS., Meador-Woodruff JH., Dalack GW.,: Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res. 1998; 33: 113-118. https://doi.org/10.1016/s0920-9964(98)00045-0
20. Cigarette smoking among adults- United States, 1991, MMWR Morb Mortal Wkly Rep. 1993; 42: 230-233. https://doi.org/10.15585/mmwr.mm6542a7
21. De Leon J., Dadvand M., Canuso C., White AO., Stanila JK., Simpson GM. : Schizophrenia and smoking: an epidemiological survey in state hospital. Am J Psychiatry. 1995; 453-455.
22. Kaisa Riala, Helina Hakko, Matti Isohanni, Anneli Pouta, Pirkko Rasanen: Is initiation of smoking associated with the prodromal phase of schzophrenia? Rev Psychiatr Neurosci. 2005;30(1):26-32
23. De Leon J., Tracy J., McCann E., McGrory A., Diaz FJ. Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. Schizophr Res. 2002; 56: 55-65. https://doi.org/10.1016/s0920-9964(01)00192-x
24. Goff DC., Henderson DC., Amico E.: Cigarette smoking in schizophrenia: relationschip to psychopathology and medication side effects. Am J Psychiatry. 1992; 149: 1189-1194. https://doi.org/10.1176/ajp.149.9.1189
25. Eastwood R.: Weeding out (letter). Lancet 1993; 341:1316.
26. Kirshnadas R., Jauhar S., Tefler S., Shivashankar S., McCreadie R.:Nicotine dependence in patients with schizophrenia. Br. J. Psychiatry. January 1, 2013 202:74-75.
27. Ziedonis DM., Kosten TR., Glazer WM., Frances RJ.: Nicotine dependence and schizophrenia. Hosp Community Psychiatry. 1994; 45:204-206. https://doi.org/10.1176/ps.45.3.204
28. Zhang XY., Xiu MH., Chen DH., Yang FD., Wu GY., Lin L., Kosten TA., Kosten TR.: Nicotine dependence and serum BDNF levels in male patients with schizophrenia; Psychopharmacology. 2010, 212:301-307. https://doi.org/10.1007/s00213-010-1956-y
29. Cigarette smoking-attributable mortality and years of potential life lost- United States, 1990. MMWR Morb Mortal Wkly Rep. 1993; 42: 645-649.
30. Tsuang MT., Woolson RF., Fleming JA.: Premature deaths in schizophrenia and affective disorders: an analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry. 1980; 37: 979-983. https://doi.org/10.1001/archpsyc.1980.01780220017001
31. Levin ED., Rezani AH. Nicotynic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol. 2007; 74: 1182-1191. https://doi.org/10.1016/j.bcp.2007.07.019
32. Fowler JS., Logan J., Wang GJ., Volkow ND. Monoamine oxidase and cigarette smoking. Neurotoxicology. 2003; 24: 75-82. https://doi.org/10.1016/s0161-813x(02)00109-2
33. Brody AL., Olmstead RE., London ED., Farahi J., Meyer JH., Grossman P., Lee GS., Huang J., Hahn EL., Mandelkern MA. Smoking-induced ventral striatum dopamine release Am J Psychiatry. 2004; 161: 1211-1218. https://doi.org/10.1176/appi.ajp.161.7.1211
34. Scott DJ., Domino EF., Hetzeg MM., Koeppe RA., Ni L., Guthrie S., Zubieta JK. Smoking modulation of muopioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology. 2007; 32:450-457. https://doi.org/10.1038/sj.npp.1301238
35. Fehr C., Yakushev I., Hohmann N., Buchholz HG., Landvogt C., Deckers H., Ebershardt A., Klager M., Smolka MN., Scheurich A., Dielentheis T., Schmidt LG., Rosch F., Bartenstein P., Grunder G., Schreckenberger M. Association of low striatal dopamine D2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry. 2008; 165: 507-514. https://doi.org/10.1176/appi.ajp.2007.07020352
36. Yang Yk., Yao WJ., Yeh Tl., Lee IH., Chen PS., Lu RB., Chiu NT. Decreased dopamine transporter availability in male smokers- a dual isotope SPECT study. Prog Neuropychopharmacol Biol Psychiatry. 2008; 32:274-279. https://doi.org/10.1016/j.pnpbp.2007.08.018
37. Morens DM., Grandinetti A., R eed D ., White LR., Ross GW.: Cigarette smoking and protection from Parkinson’s disease: false association or aetiologic clue? Neurology. 1995; 45:1041-1045. https://doi.org/10.1212/wnl.45.6.1041
38. Tregallas JR., Shatti, Tanabe JL., Martin LF., Gibson L., Wylie K., Rojas DC. Grey matter volume differences and the effects of smoking on grey matter in schizophrenia. Schizophrenia Res. 2007; 97: 242-249. https://doi.org/10.1016/j.schres.2007.08.019
39. De Luca V., Wong AHC., Muller DJ., Wong GWH., Tyndale RF., Kennedy JL. Evidence of association between smoking a nd a lfa7 n icotynic r eceptor s ubunit g ene i n s chizophrenic patients. Neuropsychopharmacol. 2004; 29:1522-1526. https://doi.org/10.1038/sj.npp.1300466
40. Freedman R., Adler LE., Bickford P., Byerley W., Coon H., Cullum CM., Griffith J., Harris JG., Leonard S., Miller C., Myles-Worsey M., Nagamoto HT., Rose G., Waldo M. Schizophrenia and nicotinic receptors. Harv. Rev. Psychiatry. 1994;2:179-192. https://doi.org/10.3109/10673229409017136
41. Braff DL., Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry. 1990;47:181-188. https://doi.org/10.1001/archpsyc.1990.01810140081011
42. Adler LE., Olincy A., Waldo M., Harris JG., Giffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia sensory gating and nicotinic receptors. Schizophr. Bull. 1998;24:189-202. https://doi.org/10.1093/oxfordjournals.schbul.a033320
43. Braff D., Freedman R. Neuropsychopharmacology. In: Davis KL, Charney D, Coyle JT, Nemeroff CN, editors. The Fifth Generation of Progress. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 703-716. https://doi.org/10.1002/hup.431
44. Maier W., Schwab S.: Molecular genetics of schizophrenia. Current Opinion in Psychiatry. 1998; 11:19-25. https://doi.org/10.1097/00001504-199801000-00014
45. Clarke PBS.: Tobacco smoking, genes and dopamine. Lancet 1998; 353:84-85.
46. Dalack GW., Haly DJ., Meador-Woodruff JH.: Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry. 1998; 155: 1490-1501. https://doi.org/10.1176/ajp.155.11.1490
47. Glynn SM., Sussman S.: Why patients smoke ( letter ). Hosp Community Psychiatry. 1990; 41: 1027-1028.
48. Lavin MR., Siris SG., Mason SE.: What is the clinical importance of cigarette smoking in schizophrenia? Am J Addict 1996; 5:189-208. https://doi.org/10.3109/10550499609041174
49. Yassa R., Lal S., Korpassy A., Ally J.: Nicotine exposure and tardive dyskinesia. Biol Psychiatry. 1987; 22:67-72. https://doi.org/10.1016/0006-3223(87)90131-4
50. Nilsson A., Walker L., Rosengren A., Aderberth A., Wilhelsen L.: Cigarette smoking is associated with abnormal involuntary movements in the general male population- a study of men born in 1933. Biol Psychiatry. 1997; 41:717-723. https://doi.org/10.1016/s0006-3223(96)00289-2
51. Levin ED., Wilson W., Rose JE., McEvoy J.: Nicotinehaloperidol interactions and cognitive performance on schizophrenics. Neuropsychopharmacology. 1996; 15:429-436.
52. Zevin S., Benowitz NL. Drug interactions With Tobacco Smoking. An update. Clin Pharmacokinet. 1999; 36: 425-438. https://doi.org/10.2165/00003088-199936060-00004
53. Ereshefsky L., Jann MW., Saklad SR., Davis CM., Richards AL., Burch NR.: Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry. 1985; 20:329-332. https://doi.org/10.1016/0006-3223(85)90063-0
54. Jann CM., Saklad SR., Ereshefsky L., Richards AL., Harrington CA., Davis CM.: Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl). 1986; 90: 468-470. https://doi.org/10.1007/bf00174062
55. Van der WeideJ, Steijns LSW.,van Weelden MJM. The effect of smoking and cytochrome P450 CYP 1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics. 2003; 13: 169-172. https://doi.org/10.1097/00008571-200303000-00006
56. Wu TH., Chiu CC., Shen WW., Lin FW., Wang LH., Chen HY., Lu ML. Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 12; 32 (8): 1889-1893. https://doi.org/10.1016/j.pnpbp.2008.08.022
57. Haselmo T., Eikeseth PH., Tanum L., Molden E., Refsum H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Pharmacol. 2006; 62: 1049-1053. https://doi.org/10.1007/s00228-006-0209-9
58. Derenne JL., Baldessarini RJ. Clozapine toxicity associated with smoking cessation: case report. Am J Ther. 2005; 12: 469-471. https://doi.org/10.1097/01.mjt.0000146622.59764.dd
59. Desai HD., Seabolt J., Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001; 15: 469-494. https://doi.org/10.2165/00023210-200115060-00005
60. George TP., Sernyak MJ., Ziedonis DM., Woods SW.: Effects of clozpine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry. 1995; 56:344-346.
61. McEvoy JP., Freudenreich O., Levin ED., Rose JE.: Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 1995; 119: 124-126. https://doi.org/10.1007/bf02246063
62. AhnAllen C., Liverant G., Gregor K, Kamholz B, Levitt J., Guliver S., Pizzagalli D., Koneru V., Kaplan G.: The relationship between reward-based learning and nicotine dependence in smokers with schizophrenia. Psychiatry Research. 2012; 196: 9-14. https://doi.org/10.1016/j.psychres.2011.09.011
63. Diaz FJ., Velasquez DM., Susce M T., De Leon J. The association between schizophrenia and smoking: unexplained by either the illness or the prodromal period. Schizophrenia Res. 2008; 104:214-219. https://doi.org/10.1016/j.schres.2008.06.004
64. Perkins DO. Predictors of nonadherence in patients with schizophrenia. J Clin Psychiatry 2002; 63: 12-16.
65. Burton S C. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. Journal of Psychiatric Practice 2005; 11: 369-378. https://doi.org/10.1097/00131746-200511000-00003
66. Fenton WS., Blyler CR., Helnssen RK. Determinants of medication adherence in schizophrenia: Empirical and clinical findings. Schizophr Bull 1997; 4: 637-651. https://doi.org/10.1093/schbul/23.4.637
67. Kazadi NJB., Moosa MYH., Jeenah F.Y. Factors associated with relapse in schizophrenia. SAJP. 2008; 14(2): 52-62.
68. Ustawa z dnia 8 kwietnia 2010r. o zmianie Ustawy o ochronie zdrowia przed następstwami używania tytoniu i wyrobów tytoniowych oraz Ustawy o Państwowej Inspekcji Sanitarnej Dz.U. z 2010 r. nr 21, poz. 105.
